TempraMed Enters Strategic Media Partnership with Dr. Phil's Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States

Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed's full product portfolio

Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has entered into a strategic media partnership with Dr. Phil and Envoy Media, providing access to an audience of over 19 million monthly viewers which marks a significant step in accelerating market adoption and brand authority across the United States.

Partnership Highlights

• Exclusive title sponsorship of a Dr. Phil television special focused on prescription medication safety

• TempraMed positioned as the featured solution within the program narrative, with no competing brands

• Multi-platform distribution across broadcast TV, podcasts, YouTube, and social media with millions of expected viewers

• Full content usage rights enable long-term monetization across paid media, digital acquisition, and B2B outreach

• Campaign supports TempraMed's transition from awareness-building to scaled demand generation and enterprise engagement

"Dr. Phil brings unmatched credibility and reach to conversations that matter deeply to patients and families," said Ron Nagar, CEO of TempraMed. "This partnership allows us to educate millions of people about a largely overlooked risk in medication use—temperature exposure—while positioning TempraMed as the clear, trusted solution for medication storage and management. For our investors, this is about accelerating awareness, demand, and enterprise engagement at national scale."

Under the agreement, TempraMed will serve as the exclusive title sponsor of a full-length, 44-minute Dr. Phil-hosted television special focused on common and often dangerous mistakes people make with prescription medications. The program is scheduled to air as a Dr. Phil Envoy TV Special in May 2026.

The special will devote airtime to TempraMed's technology, education around medication temperature safety, and real-world use cases. The segment includes an on-air interview with a TempraMed spokesperson, integrated calls-to-action, and persistent on-screen branding.